Related Experiment Video
Updated: Sep 27, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
The Systemic Immune Markers at Diagnosis Can Predict the Survival Benefit in Advanced Breast Cancer
Shogo Nakamoto1, Masahiko Ikeda1, Shinichiro Kubo1
1Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
Background/Aim:
It has been difficult to establish prognostic markers for overall survival (OS) in patients with advanced breast cancer (ABC). Although systemic immune markers were reported as prognostic markers in several cancers, their utility in ABC remains unclear.
Patients And Methods:
We retrospectively analyzed 331 ABC patients, who received treatment at Fukuyama City Hospital between April 2009 and December 2020.
Results:
Patients with high absolute lymphocyte count (ALC), low neutrophil-to-lymphocyte ratio (NLR), and high lymphocyte-to-monocyte ratio (LMR) had significantly longer OS (p=0.025, p=0.010, and p<0.001, respectively). High ALC and high LMR were independently associated with longer OS (p=0.020 and p=0.015, respectively). High ALC was also independently associated with longer time to treatment failure (p=0.014).
Conclusion:
These systemic immune markers at diagnosis can predict not only a better OS but also a better TTF after first-line treatment.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
